Applications of 4-N-Boc-2-Methyl-Piperazine in Industrial Manufacturing

Our in-house manufactured 4-N-Boc-2-Methyl-Piperazine delivers reliable performance for downstream synthesis in high-value pharmaceutical, agrochemical, and specialty chemical sectors. The following sections describe its established integration in advanced industrial processes across key market segments, with detailed guidance on compliance regimes, formulation practice, process flow, and finished goods output.

1. Active Pharmaceutical Ingredient (API) Intermediate for Antidepressant Synthesis

This molecule serves as an essential intermediate in the multi-step synthesis of key piperazine-based antidepressants, supporting manufacturing processes for innovative central nervous system drugs. Pharmaceutical end users employ it primarily at the mid-stage of the API route, where consistent protection and deprotection steps dictate critical yield and purity outcomes. Our material is batch-traceable and produced meeting the exacting demands of GMP operations targeting regulated therapies.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• 21 CFR Part 211 (US cGMP for Finished Pharmaceuticals)
• Chinese Pharmacopoeia 2025 (applicable monograph for piperazine derivatives)
• EU Guidelines for Good Manufacturing Practice (Parts I & II)

Typical usage ratio

• 1.3 – 1.8 molar equivalents per target amine group, adjusted for batch size and impurity control during Boc protection step

Downstream process integration

• Introduced during the tert-butoxycarbonyl (Boc) protection phase of the heterocyclic amine
• Subsequent deprotection for library synthesis, followed by coupling or alkylation reactions
• Inline process analytical technology monitors Boc group removal before downstream acylation

Final product types

• Finished antidepressant APIs (e.g., Paroxetine, Quetiapine intermediates)
• Research-grade CNS drug precursors
• Clinical trial batch substances

2. Key Protecting Reagent in Oncology Drug Synthesis

The compound supports the precise protection of secondary amines in the synthesis of piperazine-backbone kinase inhibitors, a critical utility during the construction of targeted anti-cancer agents. Pharmaceutical manufacturers value its selective reactivity and high purity output, ensuring consistent downstream derivatization and process reproducibility as required for patent-protected oncology drugs.

Industry compliance standards

• US FDA DMF (Drug Master File) referencing for raw materials
• European Medicines Agency Qualification of Starting Materials for Chemical APIs
• Global ICH Q3A/B guidelines for Impurities in New Drug Substances and Products

Typical usage ratio

• 0.95 – 1.05 equivalents relative to the substrate, varied according to the nitrogen content and desired selectivity in the protection stage

Downstream process integration

• Utilized as a transient protection agent during cyclization and alkylation steps of oncological API production
• Enables protection/deprotection workflows prior to selective functionalization
• Boc group removal via acidolysis immediately upstream from purification

Final product types

• Tyrosine kinase inhibitor API intermediates (e.g., Imatinib, Dasatinib synthetic steps)
• Patent-specific drug substance intermediates for solid tumor treatments

3. Intermediate in Agrochemical Synthesis for Fungicide Formulation

This material fulfills a specialized role in the stepwise construction of piperazine-based fungicides, particularly as a protected nitrogen source in pre-finish intermediates. Agrochemical formulators require rigorous traceability and low-level impurity profiles due to the end-use registration requirements governing crop protection compounds in the United States, EU, and China.

Industry compliance standards

• EPA 40 CFR Part 158 (Data Requirements for Pesticides)
• REACH Regulation (EC) No 1907/2006 (European Chemicals Agency)
• GB 2763-2022 China MRL (Maximum Residue Limits for Pesticides)
• ISO 9001:2015 Quality Management System for Agrochemical Synthesis

Typical usage ratio

• Up to 1.2 equivalents per piperazine group in early-stage intermediates; adjusted lower in late-stage steps to minimize downstream purification load

Downstream process integration

• Applied during the aminopiperazine protection sequence preceding ring-closure and side-chain introduction
• Intermediate isolated, deprotected, and further derivatized into fungicidal actives or foliar-applied agents
• Regular analytical validation performed after each stage to confirm removal of Boc group and minimize residual levels

Final product types

• Protective fungicide active ingredients (e.g., piperazine-carbamate derivatives)
• Pre-packaged suspension concentrate formulations
• Bulk intermediates for global agrochemical supply chains

4. Building Block for Custom Chemical Synthesis in Contract Manufacturing

Custom synthesis organizations source this compound to construct specialty heterocyclic units for biotech and small-molecule discovery. CMO/CDMO facilities utilize its steric properties in selective protection/deprotection cycles, offering hit-to-lead services for emerging therapeutic candidates where documentation and reproducibility stand as paramount concerns for customer validation and regulatory filings.

Industry compliance standards

• ISO 13485 (for custom synthesis in medical device reagents)
• ICH Q11 Development and Manufacture of Drug Substances
• Client project-specific quality agreements and signed technical protocols

Typical usage ratio

• Usually 1.0 equivalent relative to the primary amine to be protected; deviations dictated by the complexity of the target scaffold and the number of functional groups

Downstream process integration

• Used at the controlled Boc protection step in early phase multi-gram syntheses
• Subject to real-time in-process QC per customer-developed analytical methods
• Integrated into FTE-based synthesis programs and promptly supplied as protected intermediates

Final product types

• Milligram-to-kilogram scale reference compounds
• Lead candidate libraries for preclinical studies
• Protected heterocycle intermediates for diagnostic tools and medical research